September 2024 – Page 5

Bristol Myers Squibb Continues Layoffs, Cutting 79 More Jobs in New Jersey Amid $1.5B Cost Reduction Effort

12 months ago talkbio0Tagged Drug Industry, Financial cost, Myers, New Jersey, squibb

Bristol Myers Squibb, layoffs, New Jersey, cost reduction, pharmaceutical industry

Athira Pharma Shifts Focus to ALS After Alzheimer’s Setback, Cuts 70% of Workforce

12 months ago talkbio0Tagged Alzheimer 's disease, Amyotrophic Lateral Sclerosis, Athira Pharma, Neurodegenerative Disorders, small molecule therapy

Athira Pharma, Alzheimer’s disease, ALS, layoffs, biotech, neurodegenerative diseases, small molecule therapy

BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis

12 months ago talkbio0Tagged Alzheimer's Disease, Approved, KarXT, Mechanism (attribute), Muscarinic Agonists, Myers, Psychotic Disorders, Schizophrenia, squibb, United States Food and Drug Administration

KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.

Eli Lilly and Novo Nordisk Support OAC’s Your Weight Matters Campaign Amidst Competitive Weight Loss Drug Market

12 months ago talkbio0Tagged care activity, Drug Industry, Eli, Eli Lilly, Glucagon-Like Peptide 1, Nordisk, OAC, Obesity, Weight-Loss Agents

Eli Lilly, Novo Nordisk, OAC, Your Weight Matters, weight loss drugs, GLP-1, obesity care, pharmaceutical industry

Zevra Therapeutics Secures FDA Approval for Miplyffa, a Breakthrough Treatment for Niemann-Pick Disease Type C

12 months ago talkbio0Tagged Approved, Infrequent, Lysosomal Storage Diseases, Miplyffa, Niemann-Pick Disease, Type C, United States Food and Drug Administration

Zevra Therapeutics, Miplyffa, FDA Approval, Niemann-Pick Disease Type C, Rare Lysosomal Storage Disorder, Arimoclomol

FDA Approves AstraZeneca’s FluMist as First Self-Administered Flu Vaccine

12 months ago talkbio0Tagged Approved, AstraZeneca, FluMist, nasal spray vaccine, self-administered flu, United States Food and Drug Administration, Vaccines

FluMist, self-administered flu vaccine, FDA approval, AstraZeneca, nasal spray vaccine

Sarclisa Gains FDA Approval as First-Line Treatment for Newly Diagnosed Multiple Myeloma

12 months ago talkbio0Tagged Approved, Combined Modality Therapy, first-line, isatuximab, Multiple Myeloma, sanofi, Sarclisa, United States Food and Drug Administration, VRd

Sarclisa, FDA approval, first-line treatment, multiple myeloma, Sanofi, isatuximab, VRd combination therapy.

FDA Approves AstraZeneca’s FluMist as First Self-Administered Flu Vaccine

12 months ago talkbio0Tagged accessibility, AstraZeneca, FluMist, nasal spray influenza, self-administered flu, United States Food and Drug Administration, Vaccines

FluMist, AstraZeneca, FDA, self-administered flu vaccine, nasal spray influenza vaccine, flu prevention, influenza disease, vaccine accessibility

Gilead’s Kite Unit Exits China CAR-T Joint Venture with Fosun

12 months ago talkbio0Tagged CAR-T, Cell Therapy, China, Fosun Pharma, Gilead Sciences, Joint Ventures, Kite Pharma, Yescarta

Gilead Sciences, Kite Pharma, Fosun Pharma, CAR-T cell therapy, joint venture, China, Yescarta

Sanofi Prepares for Regulatory Submission of Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis

12 months ago talkbio0Tagged BTK Inhibitor, Clinical Research, GEMINI 1, HERCULES, Multiple Sclerosis, non-relapsing, nrSPMS, regulatory, regulatory approval, sanofi, Tolebrutinib

Tolebrutinib, BTK inhibitor, Multiple sclerosis, Non-relapsing secondary progressive multiple sclerosis (nrSPMS), Sanofi, HERCULES study, GEMINI 1 and 2 studies, Regulatory approval